NEW YORK, March 1 (Reuters) - Amgen Inc. management moved on Thursday to reassure investors that the majority of use of its biggest product, the anemia drug Aranesp, will continue despite mounting ...
April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
Breast cancer patients (N = 354) receiving chemotherapy were randomly assigned in 1:1 ratio to epoetin alfa (40,000 U qw) or standard of care (SOC). QOL was assessed at baseline and week 12.
Early results from a novel treatment strategy for chemotherapy-related anemia: Epoetin alfa 60,000 U SC QW induction followed by 60,000 U SC Q2W Conclusions: Epoetin alfa was safe and well tolerated ...
Shares of Amgen are rallying $1.54, or 4.3 percent, to $37 in pre-open trading after the U.S. Food and Drug Administration approved the biotech firm's Aranesp for the treatment of chemotherapy-induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results